



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

May 10, 2022: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Medical Director Update** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Letrozole Use for Infertility
 - Introduce: Opioid Use from Multiple Providers

- **Clinical Update: Drug Reviews** **7:20-7:55**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - Releuko® (filgrastim-ayow)

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Livmarli® (maralixibat)
 - Skytrofa® (lonapegsomatropin-tcgd)
 - Thyquidity™ (levothyroxine sodium)
 - Tyrvaya® (varenicline solution)

- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
 - None at this time
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:25**
(Public comment prior to Board action)
 - Atopic Dermatitis (new drug Adbry® (tralokinumab-ldrm), Cibinqo® (abrocitinib) and Opzelura® (ruxolitinib) included)

- Bladder Relaxants
- Benign Prostatic Hyperplasia (BPH) Agents
- Colony Stimulating Factor (CSF) Agents (biosimilar Releuko® (filgrastim-ayow) included)
- Erythropoietin Stimulating Agents
- Immunosuppressants
- Idiopathic Pulmonary Fibrosis (IPF)
- Movement Disorder
- Select Contraceptive Agents

- **Review of Newly Developed/Revised Criteria** **8:25 - 8:30**
(Public comment prior to Board action)
 - Tranexamic Acid

- **General Announcements** **8:30 – 8:30**

- **Adjourn** **8:30**